Premier Graphene

Premier Graphene OCF Margin

The Operating Cash Flow Margin of Premier Graphene (BIEI) as of Nov 4, 2026 is -6,993.81 %. In the previous year, Operating Cash Flow Margin was -2,410.06 % — a change of 190.19% (lower).

OCF Margin

-6,993.81 %

YoY

190.19%

Last updated:

Operating Cash Flow Margin of Premier Graphene is 2020 -6,993.81 % . Operating Cash Flow Margin of Premier Graphene was 2019 -2,410.06 % . It decreases by 190.19% lower compared to the previous year.

The Premier Graphene OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-1,275.41 USD
Jan 1, 2018
-1,117.92 USD
Jan 1, 2019
-2,410.06 USD
Jan 1, 2020
-6,993.81 USD
The Premier Graphene OCF Margin history
YEAROCF MarginYoY
-6,993.81 %+190.19%
-2,410.06 %+115.58%
-1,117.92 %-12.35%
-1,275.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Premier Graphene Stock analysis

What does Premier Graphene do? Premier Biomedical Inc is a US biotechnology company based in Jacksonville, Florida. The company was founded in 2010 and primarily focuses on the development and marketing of groundbreaking, patented therapies and medications for a wide range of diseases. The history of Premier Biomedical Inc began when the company started developing innovative technologies and solutions for patients with chronic illnesses. The company grew quickly and established itself in the medical industry due to its innovative product development and reliability. The business model of Premier Biomedical Inc is simple - the company focuses on developing medications and therapies that are tailored to meet the needs of patients and revolutionize our industry. Additionally, the company collaborates closely with other industry partners to promote the growth and development of healthcare and biotechnology companies in the region. The company is divided into multiple divisions that focus on different types of therapies and medications. One main division is the development of pain therapies that target the strengthening and regeneration of muscle and joint tissues. This division specifically focuses on chronic pain caused by obesity, arthritis, back pain, or injuries. Another division of Premier Biomedical Inc is dedicated to combating cancer. The company works on inhibiting the growth of cancer cells and destroying them by developing innovative immunotherapeutic treatments that target specific types of cancer. Furthermore, the company is involved in the development of medications to treat PTSD symptoms caused by traumatic experiences such as injuries, combat deployments, or abuse. Premier Biomedical Inc offers a wide portfolio of products, including pain medications for the treatment of muscle pain and injuries, immunotherapies to combat cancer, and medications for the treatment of PTSD symptoms. An innovative treatment includes the removal of blood clots from the body to protect against cardiovascular diseases. In addition to its products and therapies, Premier Biomedical Inc emphasizes its commitment to sustainability and environmental protection. The company places great importance on sustainability and invests in proactive and environmentally friendly business practices to have a positive impact on the environment. Overall, Premier Biomedical Inc is an innovative company constantly searching for new and groundbreaking solutions for patients. The company actively works to improve the lives of people worldwide by developing innovative treatments for a wide range of diseases. Premier Graphene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Premier Graphene stock

Operating Cash Flow Margin of Premier Graphene is -6,993.81 % in 2020.

Operating Cash Flow Margin of Premier Graphene changed from -2,410.06 % to -6,993.81 %, representing a 190.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Premier Graphene since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Premier Graphene with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Premier Graphene

All Key Metrics — Premier Graphene